Verona Pharma plc Files 8-K Report
| Field | Detail |
|---|---|
| Company | Verona Pharma PLC |
| Form Type | 8-K |
| Filed Date | Sep 24, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, corporate-actions
TL;DR
Verona Pharma dropped an 8-K on 9/24/25 covering votes, Reg FD, and financials.
AI Summary
On September 24, 2025, Verona Pharma plc filed an 8-K report detailing several events. The filing includes information on matters submitted to a vote of security holders, Regulation FD disclosures, and other events, as well as financial statements and exhibits. The company is incorporated in the United Kingdom and its principal executive offices are located in London.
Why It Matters
This 8-K filing provides an update on Verona Pharma's corporate activities, including potential shareholder votes and regulatory disclosures, which are important for investors to monitor.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not appear to contain any immediate negative news or significant financial changes.
Key Players & Entities
- Verona Pharma plc (company) — Registrant
- September 24, 2025 (date) — Date of earliest event reported
- 3 More London Riverside London SE1 2RE United Kingdom (location) — Address of principal executive offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
What is the significance of the Regulation FD Disclosure?
Regulation FD (Fair Disclosure) ensures that material non-public information is disclosed to all investors simultaneously, preventing selective disclosure.
What type of financial statements are included in the filing?
The filing states that 'Financial Statements and Exhibits' are included, but the specific nature or period of these statements is not detailed in the excerpt.
When was Verona Pharma plc incorporated?
Verona Pharma plc is incorporated in the United Kingdom, as stated in the filing.
What is the company's SIC code?
The Standard Industrial Classification (SIC) code for Verona Pharma plc is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,219 words · 5 min read · ~4 pages · Grade level 12.8 · Accepted 2025-09-24 16:20:48
Filing Documents
- tm2526799d1_8k.htm (8-K) — 40KB
- tm2526799d1_ex99-1.htm (EX-99.1) — 28KB
- tm2526799d1_ex99-1img001.jpg (GRAPHIC) — 24KB
- 0001104659-25-092968.txt ( ) — 272KB
- vrna-20250924.xsd (EX-101.SCH) — 3KB
- vrna-20250924_lab.xml (EX-101.LAB) — 33KB
- vrna-20250924_pre.xml (EX-101.PRE) — 22KB
- tm2526799d1_8k_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On September 24, 2025, Verona Pharma plc (the "Company") held a meeting of shareholders convened with the permission of the High Court of Justice of England and Wales (the "Court" and, such meeting, the "Court Meeting") and a general meeting of shareholders (the "General Meeting" and, together with the Court Meeting, the "Shareholder Meetings"), in each case in connection with the previously announced transaction whereby Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Merck Sharp & Dohme LLC, a New Jersey limited liability company, will acquire the entire issued and to be issued share capital of the Company (the "Transaction") pursuant to a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme of Arrangement"). The Company filed its Definitive Proxy Statement on Schedule 14A for the proposals voted on at the Shareholder Meetings with the Securities and Exchange Commission on August 18, 2025, as supplemented on September 9, 2025 (the "Definitive Proxy Statement"). As of 6:30 p.m. (U.K. time) on September 22, 2025, the voting record time for the Shareholder Meetings, the Company's issued share capital consisted of 703,189,462 ordinary shares carrying one vote each. Holders of 561,232,893 ordinary shares of the Company were represented in person or by proxy at the Court Meeting. Holders of 561,119,962 ordinary shares of the Company were represented in person or by proxy at the General Meeting, which constituted a quorum for purposes of the General Meeting. All votes at both the Court Meeting and the General Meeting were conducted on a poll. The final results of voting on each of the items submitted to a vote of the Company's shareholders at the Court Meeting and the General Meeting are set forth below. The consummation of the Transaction remains subject to closing conditions, including the sanction of the Scheme of Arrangement by the Court. Co
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. Results Announcement Press Release On September 24, 2025, the Company issued a press release announcing the results of the Shareholder Meetings and an updated expected timetable of principal events. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference and constitutes a part of this report. The information included under Item 7.01 in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Other Events
Item 8.01 Other Events. Court Sanction Hearing Timing and Attendance The hearing at which the Court will be asked to sanction the Scheme of Arrangement (the "Court Sanction Hearing") has been scheduled for October 6, 2025 and will be held at The Royal Courts of Justice, The Rolls Building, 7 Rolls Buildings, London EC4A 1NL, United Kingdom. Details of the Court Sanction Hearing will be available on the Court service website on the day before the Court Sanction Hearing. Holders of ordinary shares in the Company are entitled to attend the Court Sanction Hearing, should they wish to do so, in person or through counsel.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description of Exhibit 99.1 Press Release, dated September 24, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERONA PHARMA PLC Date: September 24, 2025 By: /s/ David Zaccardelli, Pharm. D. Name: David Zaccardelli, Pharm. D. Title: President and Chief Executive Officer